AML	Acute Myeloid Leukemia.
FLT3i	FLT3 inhibitors.
FLT3mut	FLT3 mutated.
FLT3ITD	FLT3 internal tandem duplication.
FLT3TKD	Tyrosine kinase domain mutations
JM	Juxtamembrane.
HSCT	Allogeneic Hemopoietic Stem Cell Transplantation.
R/R	Relapsed/refractory.
PDGF	Platelet-derived growth factor.
OS	Overall survival.
EFS	Event free survival.
DFS	Disease free survival.
CCR	Composite complete remission.
Cri	Complete remission with incomplete hematologic recovery.
CRp	Complete remission with incomplete platelet recovery.
VEGF	Vascular endothelial growth factor.
RFS	Relapse free survival.
ORR	Overall Response rate.
MRD	Minimal residual disease.
MRDneg	Negative minimal residual disease.
MRDpos	Positive minimal residual disease.
GVHD	Graft-versus-host disease.
FL	FLT3 ligand.
VAF	Variant allel frequency.
CCT	Conventional chemotherapy.
LIT	Low intensity therapy.
PCR	Polymerase chain reaction.
WES	Whole exome sequencing.
CR	Complete remission.
FGF2	Fibroblast growth factor 2.
CRISPR-Cas9	Unbiased genome-wide clustered regularly interspaced short palindromic repeats.
GLS	Glutaminase.
Rac1	Ras-related C3 botulinum toxin substrate 1.
LSCs	Leukemic stem cells.
OME	Omacetaxine mepesuccinate.
BID	Bis in die.
HMA	Hypomethylating agents.